Background: Methotrexate (MTX), a folate anti-metabolite, has been used widely in the treatment of plenty of malignancies. However, the clinical use is limited because of its poor water solubility (BCS class II drug), nonspecific distribution, drug resistance, short circulation half-life, and toxicity. The objective of the present research was to synthesize the ester prodrug of MTX with d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) and characterize for in vitro anticancer efficacy. Results: The FTIR and NMR results revealed the successful synthesis of the prodrug. The assay and saturation solubility of the prodrug is found to be 23 ± 2.5% and 6.7 ± 1.3 mg/mL (MTX equivalent) respectively. The CMC of the prodrug in distilled water at room temperature is found to be 36.9 ± 2.6 μg/mL. The prepared prodrug micelles showed a mean particle size of 166 ± 10 nm (PDI, 0.325 ± 0.09). Further, the TEM results confirmed the self-assembling character of the prodrug into micelles with a nearly spherical shape. The prodrug caused the significantly (p < 0.01) less hemolysis (16.8 ± 1.5%) when compared to plain MTX solution and significantly higher (p < 0.01) in vitro cytotoxicity, cell cycle arresting, and apoptosis against human breast cancer cells (MCF-7 and MDA-MB-231). Conclusion: Our study results revealed the remarkable in vitro anticancer activity of MTX following its esterification with TPGS. However, further, in vivo studies are needed to prove its efficacy against different cancers.
15 December 2022 in Annales Pharmaceutiques Françaises
Background: Breast cancer is the leading and most frequent cancer among women worldwide, with rapidly growing new cases diagnosed, surpassing lung cancer. The current study aims to design, optimize and characterize Letrozole (LTZ) Loaded Ethosomes (LTZ-ETH) for the treatment of breast cancer. Materials and Methods: Ethosomes were optimized using a two-factor, three-level (32) factorial design technique. The ethosomes were characterized by vesicle size, zeta potential and entrapment efficiency. The optimized LTZ-ETH was tested for surface morphology and in vitro cytotoxicity. Results: The optimized LTZ-ETH has flawed round-shaped unilamellar structures with an average vesicle size of 218.6 ± 5 nm and an entrapment efficiency of 92.45±3.42%. Optimized LTZ-ETH demonstrated significant (p<0.01) in vitro cytotoxicity (IC50: 23.27±1.48 μg/mL) than LTZ (58.70±2.46 μg/mL) against MCF-7 Cells. Compared to LTZ, LTZ-ETH treatment caused apoptosis of large proportion of cancer cells. The above results could be correlated to the increased cell uptake of LTZ-ETH as shown by in vitro cell uptake study. Furthermore, the in vitro skin permeation study results revealed enhanced penetration of LTZ-ETH into the deeper layers of the skin. Conclusion: The study results revealed that LTZ-ETH could be used as a potential alternative treatment approach to conventional chemotherapy. However; further in vivo animal studies are required to establish its efficacy in the treatment of breast cancer.